DYNE THERAPEUTICS INC

Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

06 May 2021 06:29:00 By Nasdaq GlobeNewswire

New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting

27 Apr 2021 15:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

04 Mar 2021 06:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer

04 Mar 2021 06:25:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs

08 Feb 2021 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $168 Million Public Offering

20 Jan 2021 19:05:29 By Nasdaq GlobeNewswire

Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

10 Jan 2021 14:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 06:30:00 By Nasdaq GlobeNewswire